Clinical trials
High Risk Acute Myeloid Leukemia clinical trials
Below are recruiting high risk acute myeloid leukemia clinical trials, each written for real people, not researchers. We’re tracking 206 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07044544RecruitingPhase 1
New drug combo in stem cell transplant for myeloid cancers
This trial tests adding two new drugs, decitabine and venetoclax, to a standard reduced-intensity stem cell transplant for people with certain types of leukemia or myelodysplastic syndrome. The goal is to see if this combination can improve outcomes.
Birmingham, AlabamaAges 18–75 - NCT07014462Enrolling by invitationPhase 1
Venetoclax and dexamethasone for untreated AML
This trial tests a combination of two oral medicines (venetoclax and dexamethasone) for people with newly diagnosed AML who cannot have or choose not to have high-dose chemotherapy. The goal is to see if this gentler treatment is safe and tolerable.
Burlington, VermontAges 18 years+ - NCT07020533RecruitingPhase 1
CMV vaccine for stem cell transplant recipients
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
Duarte, CaliforniaAges 18–75 - NCT07012044RecruitingPhase 1
Cedazuridine and decitabine after stem cell transplant for childhood leukemia
This trial tests if adding two chemotherapy drugs (cedazuridine and decitabine) along with a growth factor (filgrastim) can help prevent leukemia from coming back after a stem cell transplant. It is for children and young adults with high-risk acute myeloid leukemia who are in remission after transplant.
Birmingham, AlabamaAges Up to 21 years - NCT06994676RecruitingPhase 1
Study of CBX-250 for advanced myeloid leukemias
This study tests an experimental drug, CBX-250, for people with certain advanced blood cancers (like AML) that have not responded to standard treatments or have returned. The drug works only for people who have a specific genetic marker (HLA-A*02:01). The goal is to see if it is safe and how well it works.
Duarte, CaliforniaAges 12 years+ - NCT06880354RecruitingPhase 1
Dual-target CAR-T cells for relapsed or refractory AML
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
TianjinAges 18–70 - NCT06990321RecruitingPhase 3
Cytarabine and venetoclax for older adults with AML
This trial tests a combination of two chemotherapy drugs, medium-dose cytarabine and venetoclax, as a follow-up treatment (consolidation) to keep leukemia from coming back. It is for older adults with intermediate or high-risk acute myeloid leukemia who have already achieved remission after their first round of therapy.
Changchun, JilinAges 60–75 - NCT06969430RecruitingPhase 1/Phase 2
Debio 1562M for relapsed or refractory AML
This trial tests a new drug called Debio 1562M for people with AML that has not responded to treatment or has come back. It aims to see if the drug is safe and can help fight the leukemia.
Duarte, CaliforniaAges 18 years+ - NCT06930352RecruitingPhase 2
Ziftomenib for newly diagnosed AML with NPM1 or KMT2A changes
This trial tests an oral drug called ziftomenib for people with a type of acute myeloid leukemia (AML) that has certain genetic changes (NPM1 mutation or KMT2A rearrangement) and who are not able to receive standard chemotherapy. The goal is to see if ziftomenib can help control the leukemia.
Columbus, OhioAges 18 years+ - NCT06928662RecruitingPhase 1/Phase 2
Chemo, radiation, and donor stem cell transplant for high-risk blood cancers
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
Seattle, WashingtonAges 18 years+ - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Birmingham, AlabamaAges 18–66 - NCT06846606RecruitingPhase 1
Study of AUTX-703 for advanced blood cancers
This trial tests an experimental drug, AUTX-703, for people with certain blood cancers (AML or MDS) that have returned or not improved after other treatments. The goal is to see if the drug is safe and helps control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06409936RecruitingPhase 2
Early use of asciminib for new CML patients
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
BarcelonaAges 18 years+ - NCT06839456RecruitingPhase 1/Phase 2
Stem cell addback to prevent infections after transplant
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
Philadelphia, PennsylvaniaAges 1 month–25 years - NCT06816134RecruitingPhase 2
TmBU chemo before stem cell transplant for high-risk leukemia
This clinical trial tests a new combination of chemotherapy drugs (called TmBU) before a stem cell transplant for people with high-risk or relapsed acute leukemia. The goal is to see if this conditioning regimen works better and is safe for patients who need a transplant.
Suzhou, JiangsuAges 15–65 - NCT06810583RecruitingPhase 1
Dalbavancin to prevent infections in children with high-risk leukemia
This trial tests whether an antibiotic called dalbavancin, given to prevent bacterial infections during chemotherapy-induced low white blood cell counts, is safe and works in children and young adults with certain types of leukemia. It may help reduce the risk of serious infections during treatment.
Memphis, TennesseeAges Up to 25 years - NCT06811233RecruitingPhase 2
Metal detox during AML treatment
This trial tests whether monitoring and rebalancing metals in the body can help improve treatment for adults with acute myeloid leukemia (AML) or related conditions. It's for patients who are getting their first or second round of therapy and aren't yet in remission.
Houston, TexasAges 18 years+ - NCT06802315RecruitingPhase 2
Radiation therapy before stem cell transplant for high-risk blood cancers
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
Chicago, IllinoisAges 18–65 - NCT06782542RecruitingPhase 2
A new drug combo for newly diagnosed AML with IDH1 mutation
This trial tests a combination of olutasidenib, venetoclax, and azacitidine for people with newly diagnosed acute myeloid leukemia (AML) that has an IDH1 mutation. It is for patients who are healthy enough for intensive chemotherapy. The goal is to see if this drug combination works better than standard treatment.
Miami, FloridaAges 18–75 - NCT05237258Recruiting
Compare palliative care approaches for people with high-risk AML
This study tests a specialized (targeted) palliative care program versus usual oncology care for people hospitalized with high-risk acute myeloid leukemia (AML). The goal is to see if this palliative approach improves comfort, support, and care planning during intensive treatment.
Birmingham, AlabamaAges 18–120 - NCT06458257Recruiting
Stem cell transplant for high-risk AML with CEBPA mutation
This trial tests whether a stem cell transplant from a donor can help people with a specific type of acute myeloid leukemia (AML) that has a high risk of coming back. It is for patients who have the CEBPA gene mutation and other high-risk features.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06717958RecruitingPhase 2
Ivosidenib after stem cell transplant for IDH1-mutated AML or MDS
This trial tests whether taking ivosidenib after a stem cell transplant can help prevent leukemia from coming back in people with a specific gene change called IDH1. It may be an option if you have AML or MDS with that mutation and are recovering from transplant.
AachenAges 18–75 - NCT06681363Recruiting
Leukemia and MDS biobank study at Nantes Hospital
This trial creates a biobank of blood or bone marrow samples from patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or high-risk myelodysplastic syndrome (MDS). It aims to collect samples for future research, which may help develop better treatments.
NantesAges 18 years+ - NCT06660368RecruitingPhase 2
A study of a drug combo for relapsed or refractory AML
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
Tampa, FloridaAges 18–80
Hear when a new High Risk Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high risk acute myeloid leukemia?
- Yes. Clin2 currently lists 206 recruiting high risk acute myeloid leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high risk acute myeloid leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high risk acute myeloid leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.